Ena Bromley

Background

About Ena Bromley

We are serving the patient populations of the diseases we investigate. Towards this, my life goal is to make my experience available to improve the ways we collect, interpret and share complex data in the design, analyses and implementation of clinical studies as it relates to drug and vaccine development, especially as it relates to target discovery for complex diseases. My expertise in high dimensional analytics brings an unique knowledge base to the table that combines complex data analytics with clinical relevance towards drug discovery and regulatory approval. I have been involved with over 400 preclinical, clinical and device studies across an array of diseases with an early focus on oncology, neurodegenerative and infectious disease that expanded to consulting of complex clinical trial design across several disease modalities. As serial entrepreneur I cofounded Oyanalytika, Inc. in 2021 and joined forces with The Life Sciences Division after my previous company, BioStat Solutions, Inc. was acquired by PharmaLex in 2020. When we all work together, everyone wins. Our combined experience helps us to think of innovative ways to combine knowledge and turn it into wisdom to ultimately make the world a better place.